Meropenem and Orgaran drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Meropenem (meropenem) and Orgaran (danaparoid sodium). Common drug interactions include upper respiratory tract inflammation among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Meropenem and Orgaran. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

What is Orgaran?

Orgaran has active ingredients of danaparoid sodium. eHealthMe is studying from 863 Orgaran users. Check the latest studies of Orgaran.

On Jul, 14, 2026

37 people who take Meropenem and Orgaran together, and have interactions are studied.

Meropenem and Orgaran drug interactions.

What are the common drug interactions of Meropenem and Orgaran, by gender? *:

female:

Upper respiratory tract inflammation
Vomiting
Weight increased
White blood cell count decreased
Brain stem haemorrhage (bleeding into structures of brain stem)
Circulatory collapse
Fungaemia (fungi circulate in the blood)
Infection
Multi-organ failure (multisystem organ failure)
Renal failure (kidney dysfunction)

male:

Anaemia (lack of blood)
Acute respiratory distress syndrome
Gastric varices
Haematemesis (vomiting of blood)
Varices oesophageal (enlarged and swollen veins at the bottom of the oesophagus, near the stomach)
Portal hypertension (increase in the blood pressure within a system of veins called the portal venous system)
Splenic embolism (obstruction in splenic artery)
Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
Mental disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability)
Renal impairment (severely reduced kidney function)

What are the common drug interactions of Meropenem and Orgaran, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Precursor t-lymphoblastic lymphoma/leukaemia recurrent (precursor b-cell cancer recurrent)
Acute respiratory distress syndrome
Anaemia (lack of blood)
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Hepatosplenomegaly (enlargement of both the liver and the spleen)
Klebsiella infection
Oesophageal varices haemorrhage (bleeding from extremely dilated sub-mucosal veins in the lower third of the oesophagus)
Subileus
Thrombocytopenia (decrease of platelets in blood)
Ascites (accumulation of fluid in the abdominal cavity)

10-19:

Engraftment syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation)
Platelet count decreased
Pulmonary alveolar haemorrhage (acute bleeding)
Venoocclusive liver disease (small veins in the liver are obstructed)
Coma hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Hepatic failure (liver failure)
Immune system disorder

20-29:

Brain stem haemorrhage (bleeding into structures of brain stem)
Circulatory collapse
Fungaemia (fungi circulate in the blood)
Infection
Multi-organ failure (multisystem organ failure)
Renal failure (kidney dysfunction)
Respiratory failure (inadequate gas exchange by the respiratory system)
Staphylococcal sepsis (blood infection by an infection with staphylococcus bacteria)
Venoocclusive liver disease (small veins in the liver are obstructed)

30-39:

Anaemia (lack of blood)
Blood glucose increased
Decreased appetite
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Gastrointestinal mucosal disorder (disorder of gastrointestinal lining mucous membranes)
Generalised oedema (swelling all over the body)
Malignant neoplasm progression (cancer tumour came back)
Neuropathy peripheral (surface nerve damage)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Platelet count decreased

40-49:

n/a

50-59:

Sepsis (a severe blood infection that can lead to organ failure and death)
Anaemia (lack of blood)
Blood glucose increased
C-reactive protein increased
Decreased appetite
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Fungaemia (fungi circulate in the blood)
Gastrointestinal mucosal disorder (disorder of gastrointestinal lining mucous membranes)
Generalised oedema (swelling all over the body)
Neoplasm malignant (cancer tumour)

60+:

Renal impairment (severely reduced kidney function)
Cirrhosis alcoholic (chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue caused by alcoholism)
Gamma-glutamyltransferase increased
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Transaminases increased
White blood cell count increased
Bone marrow failure
Candida sepsis (candida in blood stream)
Melaena (the passage of black, tarry stools)
Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)

What are the existing conditions these people have? *

Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 12 people, 32.43%
Sepsis (a severe blood infection that can lead to organ failure and death): 12 people, 32.43%
Rickets (softening of bones): 12 people, 32.43%
Leukoencephalopathy (disease of the white matter in the brain): 11 people, 29.73%
Pain: 10 people, 27.03%
Bile Acid Malabsorption: 10 people, 27.03%
Urinary Tract Infection: 9 people, 24.32%
Device Related Infection: 9 people, 24.32%
Insomnia (sleeplessness): 8 people, 21.62%
Heparin-Induced Thrombocytopenia: 7 people, 18.92%

* Approximation only. Some reports may have incomplete information.

Do you take Meropenem and Orgaran?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously